Analyst Price Targets — VKTX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 12, 2026 1:16 pm | Michael Ulz | Morgan Stanley | $99.00 | $31.07 | TheFly | Viking Therapeutics price target lowered to $99 from $102 at Morgan Stanley |
| November 12, 2025 11:43 am | Edward Nash | Canaccord Genuity | $107.00 | $40.60 | StreetInsider | Viking Therapeutic (VKTX) PT Raised to $107 at Canaccord Genuity |
| October 29, 2025 9:33 am | Edward Nash | Canaccord Genuity | $106.00 | $34.93 | TheFly | Canaccord starts Viking Therapeutics with Buy on obesity potential |
| October 23, 2025 12:05 pm | — | Morgan Stanley | $102.00 | $31.42 | TheFly | Viking Therapeutics price target raised to $102 from $98 at Morgan Stanley |
| October 23, 2025 11:16 am | — | Cantor Fitzgerald | $105.00 | $31.42 | TheFly | Viking Therapeutics offered 'transformative' Q3 update, says Cantor Fitzgerald |
| April 28, 2025 1:43 pm | Joon Lee | Truist Financial | $75.00 | $25.94 | TheFly | Viking Therapeutics price target lowered to $75 from $95 at Truist |
| December 2, 2024 9:09 am | Biren Amin | Piper Sandler | $74.00 | $52.94 | StreetInsider | Piper Sandler Starts Viking Therapeutic (VKTX) at Overweight |
| November 4, 2024 3:50 pm | Yale Jen | Laidlaw | $110.00 | $63.14 | StreetInsider | Laidlaw Reiterates Buy Rating on Viking Therapeutic (VKTX) |
| November 4, 2024 11:19 am | Roger Song | Jefferies | $110.00 | $63.14 | StreetInsider | Jefferies Reiterates Buy Rating on Viking Therapeutic (VKTX) |
| June 27, 2024 4:57 am | Michael Ulz | Morgan Stanley | $105.00 | $47.39 | TheFly | Viking Therapeutics initiated with an Overweight at Morgan Stanley |
Latest News for VKTX
Viking Therapeutics, Inc. (VKTX) reached $33.84 at the closing of the latest trading day, reflecting a +2.64% change compared to its last close.
The pharmaceutical industry is currently witnessing a historic gold rush surrounding obesity treatments. While industry titans like Novo Nordisk NYSE: NVO and Eli Lilly NYSE: LLY dominate the headlines and the pharmacy shelves, the market remains hungry for a third player to disrupt the status quo.
Viking Therapeutics' leading candidate posted strong mid-stage data and is undergoing phase 3 studies. Though there are some risks, the stock could soar if it can pass the upcoming clinical and regulatory hurdles.
Novo Nordisk's stock hit a 52-week low after its REDEFINE 4 trial failed to demonstrate non-inferiority in weight loss compared to Eli Lilly's tirzepatide, marketed under the Zepbound and Mounjaro brands.
Novo Nordisk's weight-loss drug CagriSema failed to meet a critical goal in late-stage clinical trials. This shortcoming bodes well for pharmaceutical companies working on similar obesity treatments.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VKTX.
U.S. House Trading
No House trades found for VKTX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.